Building a Resilient and Equitable Health System in South Africa

By Crystal Lubbe

November 7, 2024

The article titled “DTIC Calls for a Resilient Health System” on the SAnews website highlights the critical need for a resilient health system in South Africa, as emphasised by Deputy Minister of Trade, Industry and Competition, Zuko Godlimpi. He outlines several key points regarding the importance of establishing a robust health system capable of facing various challenges.

Call for a Resilient Health System

Deputy Minister Zuko Godlimpi has made it clear that building a resilient health system is a top priority. He highlighted that this system must be robust enough to withstand healthcare challenges that may arise in the future.

Equitable Access

Deputy Minister stressed the need for equitable access to healthcare. It is vital that all segments of the population have fair and equal opportunities to receive health services, minimizing disparities in healthcare access.

Priorities

The call for a robust healthcare framework includes focusing on several key areas:
Equitable Access: Ensuring that healthcare services are accessible to everyone, especially disadvantaged communities.
Human Resources: Enhancing the development of human resources within the healthcare sector to build a stronger workforce.
Infrastructure and Resources: Upgrading healthcare infrastructure and ensuring access to essential medicines, vaccines, and other health products.
Private Sector Engagement: Engaging the private sector to play an active role in strengthening the health system.

Broader Context

This initiative is part of a broader effort to improve the health system in South Africa. It aligns with the Presidential Health Compact, which aims to strengthen the overall health system, enhance access to healthcare, and prepare for the implementation of the National Health Insurance. Through these measures, the goal remains clear: to build a health system that serves all South Africans effectively.

Reference url

Recent Posts

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

Enhertu reimbursement analysis
                 

Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

💡 How do we balance groundbreaking cancer treatments with budget realities?

The recent analysis by the Dutch Healthcare Institute on Enhertu shines a light on the complexities of integrating innovative therapies for HER2-low metastatic breast cancer into national insurance packages. While the clinical efficacy is evident, the substantial cost implications and demand for steep price reductions bring significant challenges to market access.

Explore the nuances of this vital discussion on clinical effectiveness, economic evaluation, and the future of pricing strategies in oncology.

#SyenzaNews #HealthEconomics #MarketAccess

drug price comparison
 

Global Drug Price Gaps Demand Better Drug Pricing Analysis

💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.

But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?

Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.

#SyenzaNews #healthcare #pricing

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.